Results 61 to 70 of about 11,284,409 (311)
, 2011 L-DOPA is the most commonly prescribed drug for the treatment of Parkinson's disease. Here, Moor et al. (2011) report that phenylalanyl-tRNA synthetase catalyzes the misacylation of tRNAPhe by L-DOPA, suggesting that it may contribute to the elevated ...
Eric A. First, First, Eric A.
core +1 more source
Turning Water Into a Tool: From Degradation Pathways to Functional Engineering in Halide Perovskites
Advanced Materials Technologies, EarlyView.Water exhibits a threshold‐dependent dual role in lead halide perovskites, acting either as a degradation trigger or as a powerful tool for defect passivation, recrystallization, and structural engineering. This review discusses how controlled water‐mediated interactions govern stability, dimensionality, and optoelectronic performance, providing ...
Raphaella T. S. Gonçalves +4 more
wiley +1 more source
Frontiers in Systems Neuroscience, 2011 Inhibitors of neuronal and endothelial nitric oxide synthase decrease l-3,4-dihidroxifenilalanine (L-DOPA)-induced dyskinesias in rodents. The mechanism of nitric oxide inhibitor action is unknown.
Fernando Eduardo Padovan-Neto +6 more
doaj +1 more source
Multifunctional Adhesive Hydrogel for Rapid Cardiac Hemostasis and Antibacterial Protection
Advanced Materials Technologies, EarlyView.A multifunctional polyacrylamide/gelatin/tannic acid hydrogel (PGT) is presented for rapid cardiac hemostasis under wet, dynamic conditions. Surface tannic acid coating enables instantaneous wet adhesion, accelerates coagulation, and confers antibacterial activity within a single platform.
Seoha Kim +5 more
wiley +1 more source
L-DOPA Uptake in Astrocytic Endfeet Enwrapping Blood Vessels in Rat Brain
Parkinson's Disease, 2012 Astrocyte endfeet surround brain blood vessels and can play a role in the delivery of therapeutic drugs for Parkinson’s disease. However, there is no previous evidence of the presence of LAT transporter for L-DOPA in brain astrocytes except in culture ...
M. Y. Inyushin +9 more
doaj +1 more source
The Design and Evaluation of an l-Dopa–Lazabemide Prodrug for the Treatment of Parkinson’s Disease
Molecules, 2017 l-Dopa, the metabolic precursor of dopamine, is the treatment of choice for the symptomatic relief of the advanced stages of Parkinson’s disease. The oral bioavailability of l-dopa, however, is only about 10% to 30%, and less than 1% of the oral dose is ...
Monique Hoon +3 more
doaj +1 more source
Pramipexole in comparison to l-dopa: a neuropsychological study
, 2003 Twenty right-handed patients affected by early/mild Parkinson's disease were evaluated in a randomised study using neuropsychological and clinical assessements during three treatment modalities: when in the off treatment condition, when on pramipexole ...
Pierantozzi, M +11 more
core +1 more source
Advanced Science, EarlyView.An adeno‐associated virus (AAV) toolkit enables selective anatomical and functional targeting of striatal D1‐MSNs through retrograde transduction. Enhanced capsids and engineered enhancers drive robust transgene expression across murine and primate models.
Zexuan Hong +14 more
wiley +1 more source
MoleculesThe use of phosphodiesterase inhibitors in the treatment of Parkinson’s disease is currently widely discussed. The study aimed to investigate the impact of acute and chronic treatment with the phosphodiesterase 5 inhibitor, sildenafil, at low and ...
Elżbieta Lorenc-Koci +3 more
doaj +1 more source
Fluoxetine Improves the Effect of Levodopa on 6-Hydroxy Dopamine-Induced Motor Impairments in Rats [PDF]
Advanced Pharmaceutical Bulletin, 2012 Purpose: Long term L-DOPA therapy in Parkinson’s disease is associated with troublesome motor fluctuations such as L -DOPA Induced dyskinesia and wearing off effect.
Javad Mahmoudi +3 more
doaj